First Cohort Benefits From Atsena Therapeutics XLRS Gene Therapy
UF startup Atsena Therapeutics has announced positive preliminary data for its gene therapy candidate ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
UF Health Recognized As National Leader for Treatment of Rare Inherited Disorder
UF Health has become one of only 40 VHL Alliance Clinical Care Centers in the United States.
The VHL Alliance is made up of leading healthcare organizations that specialize in treating von Hippel-Lindau (VHL) syndrome, a rare inherited disorder associated with tumors.
Hans Shuhaiber, M.D., a clinical assistant professor in the department of neurology in the UF College of Medicine and a member of the UF Health Cancer Center, said this recognition will ensure patients have access to the best treatment when they come to UF Health.
New Tool for Assessing Dehydration Is Built for Global Deployment
UF Health researchers teamed up with Brown University and researchers in Bangladesh to create FluidCalc, a tool that utilizes an algorithm to determine a patient's dehydration and calculates how much fluid they need. This tool is aimed at treating dehydration caused by diarrhea, which kills more than 1 million people each year. Until now, there hasn't been an easy-to-use tool for assessing dehydration.
Michael S. Okun, M.D., Receives Honor for Leadership and Lasting Impact in Neurology
Michael S. Okun, M.D., has been named a University of Florida Distinguished Professor. This is the highest faculty honor awarded at UF and represents Okun's dedication to leadership and his lasting impact on the field of neurology.
Okun joins seven other faculty across campus selected for the designation this year. He is only the fifth faculty member from the College of Medicine to receive this honor.
Novel Compound Opens New Avenue in Immunotherapy Treatment for Cancers
Researchers at the UF Health Cancer Center have developed a first-of-it-kind compound that may reveal a new way to treat cancer using immunotherapy. Currently, immunotherapy is among the most groundbreaking cancer treatments, but only about 20% to 40% of patients respond to it. It works by first identifying a target protein that contributes to tumor development and then developing a compound that will target that protein specifically, slowing tumor growth and boosting the body's immune system to fight off the cancer.
University of Florida Researchers Unlock New Frontiers in Brain Tumor Treatments
Researchers at the University of Florida's are making breakthroughs in the treatment of malignant brain tumors. Duane Mitchell, M.D., Ph.D., co-directs the teams conducting this research at the Preston A. Well Jr. Center for Brain Tumor Therapy at UF Health. Over the past ten years, the center has received FDA approval on 12 therapeutics and launched 13 novel immunotherapy clinical trials.
New Study Findings Could Be Key to Early Detection, Prognosis Prediction in Sepsis
A new study by seven major university medical centers, led by the University of Florida, has identified a way to predict within four days of admission whether a septic patient is at an increased risk of dying. These findings will allow patients to be given the proper care sooner, and allows health care professionals to monitor their immune suppression during care.
President’s Office Announces $10.2 Million for Fourth Round of Strategic Funding Awardees
The UF President's Office recently announced a fourth round of strategic funding to grow UF's research capabilities in critical areas of AI, space exploration, healthcare, and more.
Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis
Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.
UF Brain Institute Receives $1 Million for Stroke Research Project
The University of Florida’s McKnight Brain Institute received $1 million to support a stroke research project. The funds are part of UF President Ben Sasse’s $10.9 million strategic funding initiative aimed at boosting the university's position as a leader in critical research.
The funds will be used to launch a new project that utilizes AI to improve stroke treatments.
